Recently has been published on the journal European Review for Medical and Pharmacological Sciences a full manuscript named The safety profile of probiotic VSL#3®. A meta-analysis of safety data from double-blind, randomized, placebo-controlled clinical trials V. PANETTA, A. BACCHIERI, S. PAPETTI, E. DE STEFANI, P. NAVARRA. The study has been performed in vivo on 120 Patients (70 patients being included in three double-blind, randomized, placebo-controlled trials on 3 different indications with an observation period of an average of 197 days and 50 enrolled in an open-label observational trial ) using VSL#3®.
The main conclusions is reported as follows:
The authors concluded that the profile of safety of VSL#3®, as it emerged in the present study, is broadly comparable to those of similar probiotic medicinal products.
During the 15th Congress of ECCO (Vienna, Austria, February 12-15, 2020) has been presented a poster named The anti-inflammatory effects of the poly-probiotic VSL#3 on the oral mucosa (Marlina et al 2020).
The poster is summarizing some results coming from an in vivo study (performed at the University College London, UCL Eastman Dental Institute) double-blind placebo-controlled trial randomized 30 patients with active erosive or ulcerative oral lichen planus to probiotic (n = 15) and placebo (n = 15) groups. The conclusions were the following “In OLP, the consumption of VSL#3 seems to provide some clinical benefits, but due to the study size a more substantial multi-centre trial is necessary to confirm these observations.”
Actial Farmaceutica Srl
Viale Shakespeare 47
00144 Rome (Italy)
@ Copyright 2016. VAT number Actial Farmaceutica srl IT14019081000